# Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

> **NCT06160167** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 4204 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** IMiD treatment
- **DRUG:** No IMiD treatment
- **DRUG:** Systemic therapy

## Key facts

- **NCT ID:** NCT06160167
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 4204 (ACTUAL)
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06160167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06160167, "Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06160167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*